GAU 013-16-02

antibody from Invitrogen Antibodies

Targeting: C3 ARMD9, C3a, C3b, CPAMD1

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

GAU 013-16-02

Provider

Invitrogen Antibodies

Product name

Complement C3a Monoclonal Antibody (K13/16-5.7)

Antibody type

Monoclonal

Antigen

Other

Description

GAU 013-16-02 detects Complement Componet C3a/C3a (desArg) in human samples. This antibody does not cross-react with C4a or C5a.

Antibody clone number

K13/16-5.7

Concentration

1.00 mg/mL

References

Submitted references

Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

Sartain SE, Turner NA, Moake JL
The Journal of biological chemistry 2018 May 11;293(19):7195-7208

---

TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells.

Sartain SE, Turner NA, Moake JL
Journal of immunology (Baltimore, Md. : 1950) 2016 Jan 15;196(2):832-45

---

Peanuts can contribute to anaphylactic shock by activating complement.

Khodoun M, Strait R, Orekov T, Hogan S, Karasuyama H, Herbert DR, Köhl J, Finkelman FD
The Journal of allergy and clinical immunology 2009 Feb;123(2):342-51

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of Complement C3a in Lane 1: purified C3, lane 2: purifed C3 reduced/DTT, lane 3: purified C3a, lane 4: EDTA-plasma, Lane 5: zymosan-activated serum using a Complement C3a monoclonal antibody (Product # GAU 013-16-02).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western Blot was performed using Anti-Complement C3a Monoclonal Antibody (K13/16-5.7) (Product # GAU 013-16-02) and a 187 kDa band corresponding to Complement C3 was observed in HepG2 comparison to HEK-293 which is reported to be negative. Membrane enriched extracts (30 µg lysate) of Hep G2 (Lane 1), Hep G2 treated with Protein transport inhibitor(1X PTI for 4hr) (Lane 2), Hep G2 treated with LPS (10 ng/mL for 18 hr) followed by PTI(1X for 4hr) (Lane 3), HEK-293 (Lane 4), HEK-293 treated with PTI (1X for 4hr) (Lane 5) were electrophoresed using NuPAGE™ 4-12% Bis-Tris Protein Gel (Product # NP0322BOX). Resolved proteins were then transferred onto a Nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The Blot was probed with the primary antibody (1 µg/mL) and detected by chemiluminescence with Goat anti-Mouse IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A28177, 1:4000) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using SuperSignal™ West Dura Extended Duration Substrate (Product # 34076).

ELISA

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Sandwich ELISA of C3a/C3a (desArg) using GAU 013-16 as the capture antibody and GAU 017-01B as the biotinylated detection antibody.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL